Last reviewed · How we verify

Celtic Pharma Development Services — Portfolio Competitive Intelligence Brief

Celtic Pharma Development Services pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TDT067 TDT067 phase 3 S1P1 receptor modulator S1P1 Autoimmune diseases
Transfersome Transfersome phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Archigen Biotech Limited · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. BioLineRx, Ltd. · 1 shared drug class
  5. Bright Minds Biosciences Pty Ltd · 1 shared drug class
  6. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  7. Eric Stephen Winer, MD · 1 shared drug class
  8. Ferrer Internacional S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Celtic Pharma Development Services:

Cite this brief

Drug Landscape (2026). Celtic Pharma Development Services — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/celtic-pharma-development-services. Accessed 2026-05-14.

Related